Objective: To examine the pathological Complete Response defined as the absence of residual tumor in lung and lymph nodes comparing patients treated with chemo-immunotherapy versus chemotherapy alone. Inclusion Criteria: Exclusion Criteria: Participants: 86 Patients Treatment Groups: Primary Outcome: Secondary Outcomes: … Read More
lung cancer
LIBRETTO-431 Trial: Selpercatinib in NSCLC
Objective: To determine if the study drug selpercatinib, compared to a standard treatment, is effective and safe in participants with RET fusion-positive non-squamous non-small cell lung cancer (NSCLC) that has spread to other parts of the body. Inclusion Criteria: Participants: … Read More
NSCLC Treatment: The AEGEAN Trial Breakthrough
“Innovations in NSCLC Treatment: The AEGEAN Trial Breakthrough” In recent years, the pursuit of more effective treatments for non-small-cell lung cancer (NSCLC) has been relentless. The AEGEAN trial of 2023, as reported in the esteemed New England Journal of Medicine … Read More
KEYNOTE 671 Trial: Perioperative Pembrolizumab in Early-Stage NSCLC
KEYNOTE 671 Trial Summary Introduction:The KEYNOTE 671 trial aimed to investigate the efficacy of perioperative pembrolizumab, an immune checkpoint inhibitor, in patients with resectable early-stage non–small-cell lung cancer (NSCLC). This randomized, double-blind, phase 3 trial assessed the benefits of neoadjuvant … Read More